Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Heart Test Laboratories, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"HeartSciences Announces Further Expansion of Artificial Intelligence Patent Portfolio European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI Southlake, Texas, August 17, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences , an artificial intelligence -based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent allowance from the European Patent Office. To date HeartSciences has been granted or allowed 41 patents including nine in the U.S. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands. The..." |
|
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/19/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...|
Docs:
|
"HEART TEST LABORATORIES, INC. INCENTIVE STOCK OPTION AGREEMENT This Incentive Stock Option Agreement is entered into between Heart Test Laboratories, Inc., a Texas corporation , and __________ as of the day of . In consideration of the mutual promises and covenants made herein, the parties hereby agree as follows: 1. Grant of Option. Under the terms and conditions of the Company’s 2023 Equity Incentive Plan , which is incorporated herein by reference, the Company grants to the Optionee an option to purchase from the Company all or any part of a total of [number] shares of the Company’s Common Stock, par value $0.001 per share , at a price of $___________ per share, which will not be less than the Fair Market Value of Common Stock on the Date of Grant. Notwithstanding anything to the contra...",
"HEART TEST LABORATORIES, INC. NON-QUALIFIED STOCK OPTION AGREEMENT This Non-Qualified Stock Option Agreement is entered into between Heart Test Laboratories, Inc., a Texas corporation , and __________ as of the day of . In consideration of the mutual promises and covenants made herein, the parties hereby agree as follows: 1. Grant of Option. Under the terms and conditions of the Company’s 2023 Equity Incentive Plan , which is incorporated herein by reference, the Company grants to the Optionee an option to purchase from the Company all or any part of a total of [number] shares of the Company’s Common Stock, par value $0.001 per share , at a price of $___________ per share, which will not be less than the Fair Market Value of Common Stock on the Date of Grant unless the Agreement is otherwi..." |
|
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...|
Docs:
|
"HEART TEST LABORATORIES, INC. 2023 EQUITY INCENTIVE PLAN",
"HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results Southlake, Texas, March 16, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences , a medical technology company focused on saving lives by making an ECG a more valuable screening tool through the use of Artificial Intelligence , today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023. Key Milestones during Fiscal Q3 2023 and to date: • Engaged in multi-year collaboration with Rutgers University to develop AI-based ECG algorithms • Further international patents granted, bringing total patent portfolio to 40 • Balance sheet strengthened through the amendment and exercise of pre-IPO bridge warrants, $15 million..." |
|
| 03/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PURCHASE AGREEMENT THIS PURCHASE AGREEMENT , dated effective as of March 10, 2023, is made by and between HEART TEST LABORATORIES, INC., a Texas corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Fifteen Million Dollars of the Company’s common stock, $0.001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the “Purchase Shares.” NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for oth...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 10, 2023, is made by and between HEART TEST LABORATORIES, INC., a Texas corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: The Company has the right, upon the terms and subject to the conditions of the Purchase Agreement, to sell and issue to the Buyer up to Fifteen Million Dollars of Purchase Shares and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amend..." |
|
| 02/22/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"“3.1 Maturity Date. The outstanding Principal Amount under the FRV Note, together with all Accrued Interest thereon, shall be due and payable on September 30, 2024 . The Company paid $126,545.65 in Accrued Interest under the JQA Note on June 28, 2022 . Accrued Interest under the JQA Note from the JQA 2022 Accrued Interest Payment Date shall be due and payable on September 30, 2023 . The outstanding Principal Amount under the JQA Note, together with all Accrued Interest thereon from the JQA 2023 Accrued Interest Maturity Date, shall be due and payable on March 31, 2024 . All payments and other charges due under the Transaction Agreements shall be made in lawful currency of the United States of America.” Section 3. Release of Claims Against Lenders. THE COMPANY, BY SIGNING THIS..." |
|
| 01/11/2023 |
8-K
| Unregistered Sales of Equity Securities Interactive Data |
| 01/03/2023 |
8-K
| Quarterly results |
| 12/23/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/22/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 10/19/2022 |
8-K
| Quarterly results |
| 09/20/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/13/2022 |
8-K
| Quarterly results|
Docs:
|
"HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, September 13, 2022 – Heart Test Laboratories, Inc. d/b/a HeartSciences , a medical technology company focused on applying innovative AI-based technology to an ECG to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today provided a business update and reported financial results for the fiscal first quarter ended July 31, 2022. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are nearing completion of patient recruitment for the FD..." |
|
| 09/09/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu... |
| 08/05/2022 |
8-K
| Quarterly results |
| 07/18/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 06/15/2022 |
8-K/A
| Quarterly results |
| 06/15/2022 |
8-K
| Quarterly results |
|
|